Scientific publications

Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

Jaime Ceballos-Viro (1), José M López-Picazo [SP] (1), José L Pérez-Gracia [SP] (1), Jesús J Sola (2), Gregorio Aisa (2), Ignacio Gil-Bazo (1)
(1) Department of Oncology, Clínica Universidad de Navarra, Pio XII 36, 31008 Pamplona, Spain
(2) Department of Pathology, Clínica Universidad de Navarra, Pio XII 36, 31008 Pamplona, Spain

Magazine: World Journal of Gastroenterology

Date: May 14, 2009

Pathological Anatomy [SP] Medical Oncology

Fibrosing cholestatic hepatitis (FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver, renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic chemotherapy.

FCH constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological findings. Here, we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced immunosuppression.

This is the first reported case in the literature of FCH after conventional chemotherapy for a solid tumor. In addition to a detailed report of the case, a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.

CITATION  World J Gastroenterol. 2009 May 14;15(18):2290-2



The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra


Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra